European banks would weather an economic shock, stress tests find
AIB, Bank of Ireland, Barclays Bank Ireland, Citibank Holdings Ireland and Bank of America Europe DAC were among the banks subject to the stress test exercise.
Domhnall Cullinan, the Central Bank of Ireland's director of banking & payments supervision, said: 'On balance, the scenario in use for the EU area is broadly aligned with the 2023 exercise but the impact of the stress test is milder than the results from that exercise. This is mainly due to banks entering the exercise with stronger profitability, and stable asset quality.
'Despite prevailing uncertainty, the benefits of resilience built up in recent years are evident, with banks having sufficient capital to absorb the impact of the severe scenario. Given the uncertainty, there remains a need to maintain and continue to build resilience, both financial and non-financial.'
The Central Bank of Ireland pointed out that the stress test is not a pass or fail exercise, and no threshold is set to define the failure or success of banks. Instead, the findings inform the 2025 Supervisory Review and Evaluation Process for banks, which is conducted by joint supervisory teams made up of staff from the European Central Bank as well as the Central Bank in Dublin.
The EBA concluded that the results indicate the EU banking system could withstand a severe but plausible macroeconomic scenario, reflecting the resilience built up in recent years, but it urged lenders to maintain adequate capital.
European and American banking authorities introduced stress tests after the global financial crisis of 2008 which led to costly bailouts of banks, with Irish taxpayers among those left to pick up the tab.
Some elements of the adverse scenario used in the stress tests have already begun to materialise, the EBA pointed out, citing US President Donald Trump's tariffs and the heightened conflicts in the Middle East.
Lenders accounting for three quarters of EU banks' total assets took part in the exercise, which simulates the losses they could incur by looking at their performance over a three-year period, using both a baseline and an adverse scenario.
Under the latter, worsening geopolitical tensions and protectionist trade policies lead to an increase in energy and commodity prices, disrupt supply chains, and depress consumption and investment. This all leads to a 6.3pc contraction in EU economic output between 2025 and 2027.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Irish Times
an hour ago
- Irish Times
There's one scenario in which tariffs won't be a disaster for Ireland
I have enough grey hairs to remember trade deals being done in the past, notably the massive Uruguay round of talks which concluded in 1994 and was – though we didn't know it at the time – the high point of a long postwar drive to free world trade and reduce tariffs. The media spent many hours outside meeting rooms as negotiators from more than 120 countries went through complex line-by-line negotiations to cut tariffs and trade barriers. For Ireland, it was always a case of trading off the potential gains for industry with the threat to farmers. But over time, the State was a huge winner. The world had already started to move away from the relentless globalisation drive which had lasted well into this century. And now we have Trump's new world order and trade 'deals' which are a mix of reality, spin and fudge. We still do not know the full details of the deal between the United States and the European Union – before we even start to worry about how Trump might try to rewrite it. Ibec chief economist Gerard Brady calculates that exporters accounting for about 10 per cent of our export value to the US now know their tariff and another 10-15 per cent await news on exemptions from tariffs being negotiated between the US and the EU. The remaining 75 per cent or so of pharma and semiconductor exporters will have to wait for separate investigations now under way in the Trump administration. READ MORE There is a potential outcome from all this which, while damaging, would not be disastrous for Ireland in the short term. There will be problems, but the economy could adjust and adapt. While the Department of Finance estimates that the tariffs could lead to employment being 70,000 lower in five years' time and the economy 1.5 per cent smaller are, at best, a rough guesstimate, they do look to be in the right direction. On current trends, this would mean growth continuing, just not as quickly as it would have. We can assess the potential damage for Ireland only when we know the full details. The spirits and whiskey sectors look exposed, for example, as the US says it is a target for the 15 per cent tariffs. As this is a big issue in France, there will be an EU push in the week ahead, before final details of the deal with the US are published, to try to lower the burden here. As well as the impact on Ireland, this is one to watch at political level in the EU, as France puts pressure on Ursula von der Leyen 's European Commission , which negotiates on behalf of the EU. As butter, another vital Irish export, was already subject to a tariff of about 16-17 per cent (which will remain), things will at least not get any worse here. If we want to identify problem areas, smaller companies reliant on the US in a range of sectors is one. Small may no longer be beautiful in a complex and politically-driven world market. And it is also worth focusing on the risks to parts of rural Ireland – as highlighted by Chambers Ireland chief executive Ian Talbot – particularly those reliant on sectors such as food and also pharma and medical products. Towns such as Westport and Kinsale will anxiously await details on the pharma tariffs. [ EU-US trade deal analysis: Tariffs have a price for both sides. Trump was willing to pay it Opens in new window ] And here things remain a bit woolly, largely because the US president is undertaking study of this sector under a so-called section 232 process – referring to a section of a 1960s US act. This is separate from the big so-called reciprocal tariffs announced on Friday. The EU view is that its deal caps tariffs on pharma at 15 per cent – including any outcome from this separate process. If this holds, the sector at least knows its maximum charge. A big report – due shortly – has been drawn up for Trump under section 232, which looks at national security issues from trade and how more of the supply chain of key products can be brought back to the US from countries such as Ireland. Let's hope Trump does not revisit the 15 per cent maximum tariff figure as part of this. Tariffs are only one of Trump's policies options. On Thursday, he issued a letter to 17 of the big pharma companies demanding they cut prices in the US to the lowest level applying elsewhere. As a big buyer of pharma, the US state machinery has a lot of power here. Imposing high tariffs appears to run counter to the drive for lower prices. So the interaction between Trump and big pharma is another key thing to watch in the weeks ahead. What we do know is that the US president is determined to return pharma investment to the US and get better prices for American consumers. For Ireland, the initial impact may be slow enough to emerge. But this is likely to mean somewhat lower investment by pharma here in the years ahead and a sector which may be more focused on EU and other markets rather than exporting back to the US. Changes in the pricing and accounting practices of the multinationals – now designed to report massive profits in low-tax Ireland – are also likely to cut corporate tax revenue here. Like the rest of the economy, the Irish pharma sector will adjust. But there will be a cost, the scale of which depends on the extent of US policy action. The longer-term strategic questions will take time to clarify themselves. A major issue is whether Trump's policy direction will stick. If you are, say, a big pharma company, do you base your investments on an expectation that this is now the new world, or that Trump's policies will, in time, be rolled back either by him or by his successor? US court challenges to his powers to impose wide-scale tariffs are only now playing out. US consumer prices are surely set to rise – the only question is how much and whether there will be a cost in jobs. And the financial market calm could be upset at any time, given the crazy and risky course on which Trump has embarked. On Friday, they were already looking jumpy. So the uncertainty will roll on. Ireland should get through the first wave of this, albeit with some collateral damage. But the big question is our place in a world which seems to be breaking up into new trading blocs and alliances. And whether the valuable certainty which a final, agreed trade deal might bring can last - Ireland and Europe now needs Trump to direct his attention elsewhere.
Irish Times
2 hours ago
- Irish Times
Apple needs to up its game to impress
What does Apple have to do to impress analysts? A lot more than it is currently doing, it seems. Despite delivering a healthy set of results for its third quarter, investors seem to be unimpressed. The iPhone maker reported revenue that rose almost 10 per cent to $94 billion (€81.4 billion), with strong sales of its smartphones and momentum in China. But that wasn't enough to convince analysts that the company is on the right track. The bump in device sales was being viewed in some quarters as a reaction to potential tariffs, with lingering worries over what Donald Trump's trade war will do to Apple's future prospects. Meanwhile, the tech giant seems to be slipping further and further behind its rivals when it comes to the buzziest technology of them all: artificial intelligence . READ MORE Just over a year after the company unveiled its plans for Apple Intelligence, the speculation that Apple has lost its edge and its innovation is still rife. The tech giant has been slow to roll out new features, adopting a cautious approach to the technology even as Google and Samsung plough ahead. One of the biggest blows was the news that Apple was delaying the AI-powered, smarter version of Siri that it had previously promised. [ Is it time for a new kind of CEO at Apple? Opens in new window ] Apple has a tough line to walk. It has built its reputation on protecting the privacy of its customers, and views any developments in this area through that lens. And that means evaluating the potential impact of every decision on consumer privacy. But on Friday morning the company's shares dipped lower, extending a negative run for Apple that has seen the company's shares lose almost 17 per cent in the year to date. In contrast, one-time rival Microsoft has gained 25 per cent since the start of 2025, and Google parent company Alphabet is largely flat. Apple may have a plan up its sleeve. Chief executive Tim Cook indicated that he was open to the possibility of a deal with AI companies to help advance the technology on its platform. But that may not be enough to keep investors happy.
Irish Independent
2 hours ago
- Irish Independent
Negotiation on EU-US trade deal continues, with tariffs pushed back for another week
This gives European Commission negotiators more time to clarify details of the new trade deal, as they try to extend the range of goods to which the 15pc rate will not apply. On Thursday, the commission said it had not been able to achieve a zero-for-zero carve-out for the drinks sector. France is already pressing for parts of the deal to be renegotiated. 'It's a stage and we won't stop here,' French foreign minister Jean-Noël Barrot told broadcaster France Info. 'We want new concessions, guarantees on wine and spirits, a readjustment, [and] a rebalancing on the service sector – in particular digital services.' Speaking after a meeting of the trade forum in Government Buildings, Tánaiste and Foreign Affairs Minister Simon Harris said it was Ireland's understanding that the EU's 15pc rate was fully inclusive – incorporating existing tariffs – unlike the UK's 10pc. Confirming that pharmaceuticals will remain at a zero per cent tariff until the White House completes a Section 232 investigation – which determines how specific imports will affect US national security – Mr Harris said he had been informed by Brussels that this was likely to conclude in about two weeks. 'Without a deal between the US and the EU, today would have seen 30pc tariffs introduced by President Trump on the EU, and significant counter-measures by the EU to the tune of around €90-odd billion,' he said. 'There's absolutely no doubt that would have been a moment of catastrophe in terms of our economic well-being as a country. We'd be in a very different and a much worse position, I think, if we were standing here today with no deal. 'You don't have to take my word for that if you just see the executive order last night and all of the tariffs levelled in other countries, including countries that didn't have deals.' On Thursday night, Mr Trump signed an executive order to introduce tariffs on more than 60 countries. Most of these will take effect on August 7, but a 35pc levy on some exports from Canada came into effect immediately. The highest rates were slapped on Syria, Laos and Myanmar, which now face tariffs of about 40pc. A rate of 35pc was applied in Switzerland. The country has a big trade deficit with the US, reaching $38bn (€33bn) last year, but the White House implied that Switzerland was also being penalised for its pharma industry. ADVERTISEMENT US trade representative Jamieson Greer told BloombergTelevision: 'They ship enormous amounts of pharmaceuticals to our country. We want to be making pharmaceuticals in our country.' As usual, the extended deadline gives these countries more time to negotiate a deal with the US before the tariffs are applied. If introduced, however, it will mean the US is applying an average rate six times higher than when former president Joe Biden was in office. Stephen Innes of SPI Asset Management said: 'The average US tariff jumps from 13.3pc to 15.2pc, a seismic shift from the 2.3pc average before Trump retook office.' In a briefing to its members after the trade forum, Ibec pointed out that clarity was still needed on precisely what goods would drop to a zero tariff after August 7. 'Goods that may benefit from zero tariffs or zero-for-zero tariffs ... (including aircraft and component parts, certain chemicals, certain generic medicines, semiconductor equipment, selected agricultural products, natural resources, and critical raw materials) will require the final EU-US joint statement to confirm which specific HS codes will be exempt,' Ibec's Danny McCoy said. 'Negotiations on additional zero-for-zero arrangements not covered by the joint statement may continue in the weeks ahead.'
